Tesamorelin is a synthetic 44-amino-acid stabilized analog of growth hormone-releasing hormone (GHRH), sold as the branded product Egrifta. Its evidence and its legality both hinge on one narrow fact: the only FDA-approved use is the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy, and every other application (body composition, anti-aging, fatty liver) is off-label or gray-market territory with a weaker evidence base and added quality uncertainty. The molecule works one step upstream of growth hormone itself, prompting the pituitary to release the body's own hormone rather than replacing it.
Tesamorelin is FDA-approved solely for reducing excess visceral adipose tissue in adults with HIV-associated lipodystrophy, where pivotal 26-week trials documented a 15 to 18 percent reduction that reverses once dosing stops.
The mechanism sits one level above growth hormone. Tesamorelin is the full 44-amino-acid human GHRH sequence carrying a trans-3-hexenoic acid group on the N-terminus, a modification that shields it from dipeptidyl peptidase-4 breakdown and extends its life in circulation compared with native GHRH, which is degraded within minutes. It binds GHRH receptors on somatotroph cells in the anterior pituitary, prompting the gland to secrete the body's own growth hormone, which then drives hepatic and peripheral production of insulin-like growth factor 1 (IGF-1).
Tesamorelin acts as a GHRH-receptor agonist on the anterior pituitary, stimulating pulsatile endogenous growth hormone secretion that raises IGF-1, with a plasma half-life of roughly 25 to 40 minutes whose biological signal persists well beyond the molecule's own clearance.
The label is deliberately narrow. Tesamorelin holds a single FDA-approved indication: the reduction of excess visceral abdominal fat in adults living with HIV who have lipodystrophy, approved in November 2010 under the brand name Egrifta and marketed by Theratechnologies. This deep visceral fat is not framed as cosmetic in the registrational record; it is tied to insulin resistance, dyslipidemia, and elevated cardiovascular risk, which forms the clinical rationale. The approval explicitly does not extend to general obesity, non-HIV weight loss, athletic performance, or anti-aging, none of which were evaluated for approval.
The FDA-approved indication for tesamorelin is limited to reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy, and the label does not support use for general obesity, non-HIV weight loss, athletic performance, or anti-aging.
The most thoroughly documented effect is a selective reduction in visceral adipose tissue, the deep fat surrounding the abdominal organs. Pivotal 26-week trials recorded a roughly 15 to 18 percent reduction in that compartment measured by CT imaging, while sparing subcutaneous fat and preserving lean body mass, a selectivity that matters clinically because visceral fat is the metabolically dangerous depot. Reported secondary effects include modestly improved lipid profiles, with lower triglycerides and total cholesterol consistent with the reduced visceral adiposity.
The primary documented benefit of tesamorelin is a selective 15 to 18 percent reduction in visceral adipose tissue over 26 weeks that spares subcutaneous fat and preserves lean mass, an effect that reverses within months of discontinuation.
The published regimen is 2 mg injected subcutaneously once daily. The commercial product is reported as a lyophilized freeze-dried powder reconstituted with sterile water for injection immediately before use, gently mixed with the supplied diluent until dissolved without vigorous shaking, then drawn into a syringe and injected into abdominal fatty tissue. The literature describes daily site rotation around the stomach area to reduce localized injection-site reactions and lipoatrophy from repeated dosing in one spot.
The approved tesamorelin regimen is 2 mg reconstituted from lyophilized powder and injected subcutaneously into the abdomen once daily, with the visceral-fat effect depending on sustained daily dosing because it reverses when treatment is interrupted.
The reported side-effect profile mirrors the known consequences of raising growth hormone and IGF-1. The most commonly reported trial reactions were arthralgia, myalgia, pain in the extremities, and injection-site reactions such as redness, itching, bruising, rash, or swelling at the abdomen. Fluid retention is a recognized class effect that can produce peripheral edema or carpal tunnel-like symptoms, and because growth hormone is counter-regulatory to insulin, tesamorelin can raise blood sugar and worsen insulin resistance.
The most common documented tesamorelin reactions are arthralgia, myalgia, injection-site reactions, and fluid retention, while the drug can worsen glucose control and carries a labeled caution against use in active malignancy owing to sustained IGF-1 elevation.
Tesamorelin sits within a broader family of growth-hormone-raising compounds, and its distinctions come down to mechanism, potency, and regulatory standing. Its defining separation from the rest of the field is regulatory: it is the only member of this broad group with FDA approval and rigorous large-trial data, whereas most others including CJC-1295, ipamorelin, and various blends are sold as research chemicals or compounded products without the same evidence base or quality assurance.
| Compound | Mechanism | Regulatory standing |
|---|---|---|
| Tesamorelin | Full 44-aa GHRH analog, stabilized | FDA-approved (HIV visceral fat) |
| Sermorelin | 29-aa GHRH fragment, shorter-acting | Historically approved for pediatric growth assessment |
| CJC-1295 | GHRH analog | Research chemical / compounded |
| Ipamorelin | Ghrelin-receptor secretagogue | Research chemical / compounded |
| Recombinant HGH | Direct growth hormone replacement | Approved, but flat dosing, larger glucose disruption |
Tesamorelin is the only compound in the growth-hormone-secretagogue class with FDA approval, a defined dose, and large-trial safety and efficacy data, distinguishing it from sermorelin, CJC-1295, ipamorelin, and blends sold as research chemicals or compounded products.
Legality depends entirely on channel and purpose. The branded Egrifta product is prescription-only in the United States and cannot be legally obtained or dispensed without a prescription. Licensed prescribers may lawfully prescribe it off-label at their clinical discretion, which is how it reaches body-composition and fatty-liver use, but marketing it for those unapproved uses is not lawful, and the off-label setting lacks the evidentiary and safety backing of the approved indication.
Tesamorelin is a prescription-only drug whose legality depends on channel and purpose, with physician-supervised prescriptions legitimate while self-sourced research-chemical purchases are neither FDA-approved nor safe, and its use is banned at all times in sanctioned sport.
Branded tesamorelin is an expensive specialty medication. The Egrifta product has historically carried a cost on the order of several thousand dollars per month at list price, placing annual therapy in the tens of thousands of dollars, a figure that reflects a niche biologic-style peptide with a small patient population, complex cold-chain manufacturing, and no generic competition. Compounded tesamorelin is usually far cheaper per vial, part of its appeal, but that lower price comes with an unapproved preparation whose potency, purity, and quality control are not held to the same standard.
Branded tesamorelin has historically cost several thousand dollars per month, pushing annual therapy into the tens of thousands, with insurance typically covering only the approved HIV lipodystrophy indication under prior authorization while compounded versions trade a lower price for unverified quality.
The contraindications trace directly to the mechanism. Active malignancy is a contraindication because the drug raises IGF-1, a growth factor that can stimulate cell proliferation, and any occult malignancy is meant to be considered before starting. Pregnancy is a contraindication because reducing body weight and fat offers no benefit during pregnancy and the growth-hormone-axis effects are inappropriate for a developing fetus, with breastfeeding also discouraged.
Tesamorelin is contraindicated in active malignancy and pregnancy, requires careful evaluation in anyone with hypothalamic-pituitary axis disruption, and is not an appropriate anti-aging tool for healthy adults, whose long-term safety raising IGF-1 for cosmetic reasons is unproven.
The evidence base rests on two large, randomized, double-blind, placebo-controlled phase 3 trials in HIV-positive adults with excess visceral fat, supported by their extension phases and later mechanistic studies. Patients received either 2 mg of tesamorelin or placebo daily for 26 weeks, with the primary endpoint being percent change in visceral adipose tissue measured by CT scan at the lumbar spine. The re-randomized extension phase delivered a defining finding: patients who stopped tesamorelin regained their visceral fat, confirming that continued dosing is required to maintain the benefit.
Two phase 3 randomized controlled trials established that 2 mg of tesamorelin daily reduces visceral adipose tissue by roughly 15 to 18 percent over 26 weeks in HIV lipodystrophy, while extension data confirmed the effect requires continued dosing and the studies leave long-term and off-label safety unproven.
Educational use only. This article describes what the published scientific and clinical literature reports about Tesamorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
